Synthetic data is based on real-world data sets, used to accurately predict the ‘synthetic patient profile’ and deploy a virtual cohort in a clinical trial.
The report is the first in a series exploring the use of synthetic data in clinical development. It outlines two cases where synthetic data was used within the clinical trial process – in oncology and gastroenterology.
In oncology, trials can be costly and time-intensive – in a study without a synthetic control arm, the median R&D cost for oncology drugs is $2.77bn.
